|
XMT-2056 Clinical Trials
1 actively recruiting trial across 1 location
Pipeline
Phase 1: 1
Top Sponsors
- Mersana Therapeutics1
Indications
- HER2-positive Tumors1
- HER2-positive Non-Small Cell Lung Cancer1
- HER2-positive Colorectal Cancer1
- HER2-low Breast Cancer1
- HER2-positive Gastric Cancer1
Los Angeles, California1 trial
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
University of South California
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.